Thomas Polen, Jr. Sells 2,764 Shares of Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company (NYSE:BDX) CEO Thomas Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Becton, Dickinson and Company Trading Up 0.5%

Shares of NYSE BDX traded up $0.69 during midday trading on Wednesday, reaching $145.12. 637,556 shares of the stock were exchanged, compared to its average volume of 2,873,844. The stock has a 50 day moving average price of $151.40 and a 200-day moving average price of $176.68. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a market capitalization of $39.99 billion, a P/E ratio of 36.74, a P/E/G ratio of 10.29 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. During the same period in the previous year, the firm earned $3.35 earnings per share. Becton, Dickinson and Company’s revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities research analysts expect that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

Wall Street Analyst Weigh In

BDX has been the subject of a number of recent analyst reports. Citigroup lowered their target price on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. TD Cowen lowered their target price on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a report on Monday, May 4th. The Goldman Sachs Group lowered their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a report on Wednesday, May 27th. Zacks Research upgraded shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Finally, Jefferies Financial Group lowered their target price on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Seven equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus price target of $183.64.

Institutional Trading of Becton, Dickinson and Company

Large investors have recently added to or reduced their stakes in the stock. Brighton Jones LLC increased its holdings in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares in the last quarter. Oppenheimer Asset Management Inc. raised its holdings in Becton, Dickinson and Company by 71.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock valued at $15,471,000 after acquiring an additional 34,437 shares in the last quarter. Assetmark Inc. raised its holdings in Becton, Dickinson and Company by 49.5% in the third quarter. Assetmark Inc. now owns 225,967 shares of the medical instruments supplier’s stock valued at $42,294,000 after acquiring an additional 74,795 shares in the last quarter. Vanguard Group Inc. raised its holdings in Becton, Dickinson and Company by 0.5% in the third quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock valued at $6,074,750,000 after acquiring an additional 147,041 shares in the last quarter. Finally, Graybill Wealth Management LTD. raised its holdings in Becton, Dickinson and Company by 47.3% in the third quarter. Graybill Wealth Management LTD. now owns 27,592 shares of the medical instruments supplier’s stock valued at $5,164,000 after acquiring an additional 8,859 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.